Search

Your search keyword '"Schrama, J.G."' showing total 11 results
Start Over Author "Schrama, J.G."
11 results on '"Schrama, J.G."'

1. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

Author

Hamaker, M.E., Seynaeve, C., Wymenga, A.N.M., van Tinteren, H., Nortier, J.W.R., Maartense, E., de Graaf, H., de Jongh, F.E., Braun, J.J., Los, M., Schrama, J.G., van Leeuwen-Stok, A.E., de Groot, S.M., and Smorenburg, C.H. more...

Published
2014
Full Text
View/download PDF

2. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Author

Vollebergh, M.A., Lips, E.H., Nederlof, P.M., Wessels, L.F.A., Schmidt, M.K., van Beers, E.H., Cornelissen, S., Holtkamp, M., Froklage, F.E., de Vries, E.G.E., Schrama, J.G., Wesseling, J., van de Vijver, M.J., van Tinteren, H., de Bruin, M., Hauptmann, M., Rodenhuis, S., and Linn, S.C. more...

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

5. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Author

Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A. te, Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F.M., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A.C., Schrama, J.G., Valster, F.A.A., Velders, G.A., Koene, H.R., Dutch HOVON 64 Study Grp, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Hematology, CCA - Innovative therapy, Erasmus MC other, Clinical Chemistry, Landsteiner Laboratory, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Clinical Haematology, and Other departments more...

Subjects
medicine.medical_specialty, Immunologic Factors, Treatment outcome, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Gastroenterology, rituximab, hemic and lymphatic diseases, Internal medicine, Medicine, Dosing, Online Only Articles, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Survival analysis, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Hematology, early response, Immune thrombocytopenia, Treatment efficacy, Surgery, immune thrombocytopenia, splenectomy delaying, Rituximab, Open label, business, open label phase II, medicine.drug
Abstract

The overall short-term treatment efficacy of rituximab (R) in immune thrombocytopenia (ITP) is reported to be approximately 58%.[1][1],[2][2] With four once-weekly 375 mg/m2 doses, responses of 31% after two years,[2][2] and 21% after five years[2][2] can be expected with a median clinical more...

Published
2015
Full Text
View/download PDF

6. Dutch HOVON 64 study group. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Author

Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A.W., Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A., Schrama, J.G., Valster, F.A., Velders, G.A., and Koene, H.R. more...

Subjects
Other Research Radboud Institute for Health Sciences [Radboudumc 0], Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Contains fulltext : 155081.pdf (Publisher’s version ) (Open Access)

Published
2015

7. High D-dimer levels increase the likelihood of pulmonary embolism

Author

Tick, L.W., Nijkeuter, M., Kramer, M.H.W., Hovens, M.M., Buller, H.R., Leebeek, F.W., Huisman, M.V., Halkes, C.J., Heggelman, B.G., Nix, M., Sohne, M., Bresser, P.J., Kool, D.R., Phoa, S.S., Rekke, B., Kaasjager, K.A., Kwakkel-van Erp, J.M., Grandjean, H.M., Kesselring, F.O.H.W., Mol, J.J., Ullmann, E.F., Guldener, C. van, Mijnsbergen, J.Y., Sturm, M.F., Swart, C. de, Kuijer, P.M., Schrama, J.G., Velde, A. van de, Huisman, P.M., Eerden, M.M. van der, Janssen, P.J., Jansen, R., Lobatto, S., Compier, E.A., Eikenboom, H.C., Roos, A. de, Belle, A. van, Prins, M.H., Snoep, G., Korte, H. de, Kos, C.B., Laterveer, L., Veldhuizen, W.C. van, Kamphuizen, P.W., Bredie, S.J.H., Die, C.E. van, Heijdra, Y.F., Lenders, J.W.M., Kruip, M.J., Jie, K.S., Kars, A.H., Meiracker, A.H. van den, Pattynama, P.M., Borst, J.M. de, Houten, A.A. van, Teng, H.T., ACS - Amsterdam Cardiovascular Sciences, Vascular Medicine, and Hematology more...

Subjects
medicine.medical_specialty, Health aging / healthy living [IGMD 5], Vascular medicine and diabetes [UMCN 2.2], Malignancy, Sensitivity and Specificity, Fibrin Fibrinogen Degradation Products, Internal medicine, D-dimer, Internal Medicine, medicine, Humans, In patient, Cardiovascular diseases [NCEBP 14], business.industry, Vascular disease, Respiratory disease, Middle Aged, medicine.disease, Surgery, Pulmonary embolism, Pathogenesis and modulation of inflammation [N4i 1], Management strategy, Treatment Outcome, Cardiology, Female, business, Pulmonary Embolism, Venous thromboembolism, Tomography, Spiral Computed, Algorithms, Biomarkers
Abstract

Contains fulltext : 70029.pdf (Publisher’s version ) (Closed access) Objective. To determine the utility of high quantitative D-dimer levels in the diagnosis of pulmonary embolism. Methods. D-dimer testing was performed in consecutive patients with suspected pulmonary embolism. We included patients with suspected pulmonary embolism with a high risk for venous thromboembolism, i.e. hospitalized patients, patients older than 80 years, with malignancy or previous surgery. Presence of pulmonary embolism was based on a diagnostic management strategy using a clinical decision rule (CDR), D-dimer testing and computed tomography. Results. A total of 1515 patients were included with an overall pulmonary embolism prevalence of 21%. The pulmonary embolism prevalence was strongly associated with the height of the D-dimer level, and increased fourfold with D-dimer levels greater than 4000 ng mL(-1) compared to levels between 500 and 1000 ng mL(-1). Patients with D-dimer levels higher than 2000 ng mL(-1) and an unlikely CDR had a pulmonary embolism prevalence of 36%. This prevalence is comparable to the pulmonary embolism likely CDR group. When D-dimer levels were above 4000 ng mL(-1), the observed pulmonary embolism prevalence was very high, independent of CDR score. Conclusion. Strongly elevated D-dimer levels substantially increase the likelihood of pulmonary embolism. Whether this should translate into more intensive diagnostic and therapeutic measures in patients with high D-dimer levels irrespective of CDR remains to be studied. more...

Published
2008
Full Text
View/download PDF

8. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Author

Zwaginga, J.J. (Jaap), Holt, B. (Bronno) van der, Boekhorst, P.A.W. (Peter) te, Biemond, B.J. (Bart), Levin, M.-D. (Mark-David), Griend, R. (René) van der, Brand, A. (Anneke), Zweegman, S. (Sonja), Pruijt, H.F.M. (Hans), Novotny, V.M.J. (Vera), Vreugdenhil, A. (Art), Groot, M.R. (Marco) de, Weerdt, O. (Okke) de, Pampus, E.C.M. (Elisabeth) van, Maanen-Lamme, T.M. (Tanja) van, Wittebol, S. (Shulamit), Schipperus, M.R. (Martin), Silbermann, M.H. (Matthijs), Huijgens, P.C. (Peter), Luten, M. (Marleen), Hollestein, R. (Rene), Brakenhoff, J.A.C. (Jan), Schrama, J.G. (Jolanda), Valster, F.A.A. (Fransje), Velders, G.A. (Gerjo), Koene, H.R. (Harry), Zwaginga, J.J. (Jaap), Holt, B. (Bronno) van der, Boekhorst, P.A.W. (Peter) te, Biemond, B.J. (Bart), Levin, M.-D. (Mark-David), Griend, R. (René) van der, Brand, A. (Anneke), Zweegman, S. (Sonja), Pruijt, H.F.M. (Hans), Novotny, V.M.J. (Vera), Vreugdenhil, A. (Art), Groot, M.R. (Marco) de, Weerdt, O. (Okke) de, Pampus, E.C.M. (Elisabeth) van, Maanen-Lamme, T.M. (Tanja) van, Wittebol, S. (Shulamit), Schipperus, M.R. (Martin), Silbermann, M.H. (Matthijs), Huijgens, P.C. (Peter), Luten, M. (Marleen), Hollestein, R. (Rene), Brakenhoff, J.A.C. (Jan), Schrama, J.G. (Jolanda), Valster, F.A.A. (Fransje), Velders, G.A. (Gerjo), and Koene, H.R. (Harry) more...

Published
2015
Full Text
View/download PDF

10. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Author

Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G., Erdkamp, F.L., Vos, A.H., Groeningen, C.J. van, Sinnige, H.A.M., Richel, D.J., Voest, E.E., Dijkstra, J.R., Vink-Borger, M.E., Antonini, N.F., Mol, L., Krieken, J.H.J.M. van, Dalesio, O., Punt, C.J.A., Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G., Erdkamp, F.L., Vos, A.H., Groeningen, C.J. van, Sinnige, H.A.M., Richel, D.J., Voest, E.E., Dijkstra, J.R., Vink-Borger, M.E., Antonini, N.F., Mol, L., Krieken, J.H.J.M. van, Dalesio, O., and Punt, C.J.A. more...

Abstract

Contains fulltext : 79995.pdf (publisher's version ) (Open Access), BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. METHODS: We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome. RESULTS: The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P=0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wild-type-KRAS tumors or patients with mutated-KRAS tumors in the CB group. CONCLUSIONS: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials.gov number, NCT00208546.) more...

Published
2009